Cellectis (CLLS) Misses Q1 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Cellectis (CLLS) Misses Q1 EPS Views

Cellectis Reports First Quarter 2016 Financial Results

May 11, 2016 5:00 PM EDT

- Initiated UCART123 GMP production concept

- Secured strategic supply of key materials for GMP manufacturing

- Strong cash position of $315 million (276 million) as of March, 31 2016

NEW YORK--(BUSINESS WIRE)--

Regulatory News:

Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced its results for the three-month period ended March 31, 2016.

We are excited to monitor the results presented by... More